Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?
Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?
复制标题
免化疗放疗联合免疫检查点抑制剂：局部晚期非小细胞肺癌的新方案？
DOI：
--
复制
发表时间：
2023
影响因子：
5.5
通讯作者：
Xiangjiao Meng
中科院分区：
文献类型：
--
作者：
Lin Ma;Liufu Deng;J. Peng;Jinming Yu;Xiangjiao Meng
同步放化疗后的维持免疫治疗仍然是不可切除的局部晚期非小细胞肺癌（LA-NSCLC）患者的标准治疗方法。Pembrolizumab在IV期NSCLC中无化疗的疗效引发了对LA-NSCLC类似方法的兴趣。最近几项涉及免疫疗法与放疗（iRT）联合的协同潜力的研究已经产生了令人鼓舞的结果。本文综述了不可切除的LA-NSCLC中无化疗iRT策略的现有研究和前瞻性方向。尽管无化疗iRT策略的初步研究结果显示出有希望的疗效，但我们必须考虑当前研究的方法学局限性以及伴随无化疗iRT实施的无数挑战。这些挑战包括确定最佳剂量和分次、精确的靶体积描绘以及识别其他合适的患者队列。此外，无化疗iRT作为一种新的治疗方式选择LA-NSCLC患者的可行性取决于通过随机III期试验的验证。
Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches for LA-NSCLC. Several recent investigations involving the synergistic potential of immunotherapy combined with radiotherapy (iRT) have generated encouraging results. This review discusses the existing studies and prospective directions of chemotherapy-free iRT strategies in unresectable LA-NSCLC. Although the initial findings of chemotherapy-free iRT strategies have shown promising efficacy, we must consider the methodologic limitations of current studies and the myriad of challenges that accompany the implementation of chemotherapy-free iRT. These challenges include determining the optimal dose and fractionation, precise target volume delineation, and identification of additional suitable patient cohorts. Furthermore, the feasibility of chemotherapy-free iRT as a novel treatment modality for select patients with LA-NSCLC is contingent upon validation through randomized phase III trials.
影响因子：
50.3
作者：
Klug, Felix;Prakash, Hridayesh;Beckhove, Philipp
通讯作者：
Beckhove, Philipp
DOI：
10.1200/jco.2017.74.0720
发表时间：
2018-06-20
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Liao Z;Lee JJ;Komaki R;Gomez DR;O'Reilly MS;Fossella FV;Blumenschein GR Jr;Heymach JV;Vaporciyan AA;Swisher SG;Allen PK;Choi NC;DeLaney TF;Hahn SM;Cox JD;Lu CS;Mohan R
通讯作者：
Mohan R
DOI：
10.1016/j.ijrobp.2019.10.049
发表时间：
2020-02-01
影响因子：
7
作者：
Diffenderfer, Eric S.;Verginadis, Ioannis I.;Cengel, Keith A.
通讯作者：
Cengel, Keith A.